Arvinas– tag –
-
First PROTAC Approval Validates Targeted Protein Degradation as a Breakthrough Modality for Cancer Treatment
Converge Bio Unknown Overview The FDA approval of vepdegestrant, developed by Arvinas and Pfizer, signifies a major milestone for targeted protein degradation (TPD). This first-in-class PROTAC, approved for ER+/HER2-, ESR1-mutated advanc... -
First Oral ER PROTAC Vepdegestrant Gains FDA Approval, Ushering New Era in Targeted Protein Degradation
MDPI Switzerland Overview The field of Targeted Protein Degradation (TPD) marks a significant milestone with the FDA approval of vepdegestrant (VEPPANU, ARV-471), the first oral estrogen receptor (ER) targeted PROTAC, co-developed by Arv... -
Pfizer and Arvinas’ Veppanu (vepdegestrant) Gains FDA Approval, Revolutionizing ESR1-Mutated Advanced Breast Cancer as First PROTAC
DCAT Value Chain Insights USA Overview In 2026, Pfizer and Arvinas' Veppanu (vepdegestrant) received FDA approval for advanced breast cancer with ESR1 mutations, becoming the first FDA-approved PROTAC. This drug offers a groundbreaking o... -
Exponential Progression of Targeted Protein Degradation: First FDA-Approved PROTAC and Molecular Glues Unlock “Undruggable” Targets
MarinBio (Appears to be a scientific review/journal, affiliated with MarinBio, hence using their domain) USA Overview The field of targeted protein degradation (TPD) is rapidly evolving, enabling the degradation of previously "undruggabl... -
Arvinas/Pfizer’s PROTAC Drug Veppanu Receives Historic FDA Approval for ESR1-Mutant Advanced Breast Cancer, Demonstrating 43% PFS Risk Reduction
Cancer Discovery - AACR Journals USA Overview Arvinas and Pfizer's oral PROTAC drug, Veppanu, has received FDA approval for advanced breast cancer with ESR1 mutations, marking the first clinical validation of targeted protein degradation... -
Arvinas Accelerates Clinical Development of ARV-027 for Kennedy’s Disease, Targeting Mutant Androgen Receptor Degradation with PROTAC
Kennedy's Disease Association USA Overview Arvinas is steadily advancing the clinical development of ARV-027, an investigational PROTAC degrader for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy, SBMA). ARV-027 is designed to sel... -
Arvinas Secures IND Clearance for Oral LRRK2 Degrader ARV-102, Expanding Neurodegenerative Pipeline and Partnering with Michael J. Fox Foundation
Arvinas Press Release / MarketBeat / GLOBE NEWSWIRE USA Overview Arvinas announced FDA approval of its Investigational New Drug (IND) application for ARV-102, an oral PROTAC protein degrader designed for specific neurodegenerative diseas...
1